Long-acting growth hormone: an updated Growth Hormone Research Society consensus statement
Abstract
Long-acting growth hormone (LAGH) preparations have moved from development to routine clinical use over the past decade. Several products are now approved for paediatric growth hormone deficiency (GHD), selected non-GHD short-stature indications, and, in some regions, for adult GHD. The Growth Hormone Research Society convened an international workshop in October 2025 to reappraise the evidence base and refine clinical recommendations. Currently, data are available for up to 7 years of LAGH treatment in over 8000 individuals. This remains substantially shorter and smaller than for daily GH. Across preparations, short- to mid-term efficacy appears comparable to daily somatropin, provided dosing is individualized and monitored appropriately. Approvals and pivotal trials include both treatment initiation and switching from daily GH, depending on product and regional label. No new major safety signals have been identified in trials and real-world reports, although data on BMI trajectories require further evaluation. Injection-site reactions remain the most frequent adverse event and vary by formulation. Anti-drug antibodies have been observed, yet evidence suggests they have limited clinical impact. Effects on glucose metabolism resemble those of daily therapy, but metabolically, high-risk groups are under-represented in studies. Among cancer survivors, data on tumour recurrence and second neoplasms with LAGH are not yet available. Recommendations and practice points emphasized careful patient selection and counselling, product-specific dosing, and insulin-like growth factor-I (IGF-I) monitoring. Urgent knowledge gaps include transition care, long-term efficacy, adherence, and safety in cancer survivors. Well-resourced registries are essential for addressing these gaps and supporting safe, effective, and patient-centred use of LAGH.
Related
- Reflections on the ESC consensus statement on inflammation in coronary syndromes: From mechanistic certainty to practical cardiology
- Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement
- Expert Consensus-Based Clinical Practice Guidelines for Care and Weaning Procedures in Tracheostomized ICU Patients after Invasive Mechanical Ventilation: A Joint Statement by the Intensive Care Physiotherapy Society (SKR) and the French Intensive Care Society (SRLF)
- Hormone oscillations preserve cellular responsiveness to future physiological demands
- Exogenous Melatonin Alleviates High- and Low-Temperature Stress in Cucumber Seedlings and Regulates Hormone Signaling-Related Transcriptional Responses
BibTeX
@article{schilbach2026longacting,
title = {{Long-acting growth hormone: an updated Growth Hormone Research Society consensus statement}},
author = {Katharina Schilbach and Peter Clayton and Nidhi Agrawal and Mai Arlien-Søborg and Philippe Backeljauw and Beverly Biller and Cesar Boguszewski and Margaret Boguszewski and Philippe Chanson and Pierre Chatelain and Stefano Cianfarani and Maria Fleseriu and Judith Gebauer and Adda Grimberg and Ken Ho and Andrew Hoffman and Gudmundur Johannsson and Jens Jorgensen and Anders Juul and Wolfram Karges and Jan Lebl and Xiaoping Luo and Mohamad Maghnie and Aristides Maniatis and Bradley Miller and Sebastian Neggers and Michel Polak and Sally Radovick and Lars Sävendahl and Junia Schweizer and Paulo Collett-Solberg and Adam Stevens and Christian Strasburger and Christa van Bunderen and Haim Werner and Joachim Woelfle and Kevin Yuen and Martin Bidlingmaier},
journal = {European Journal of Endocrinology},
year = {2026},
month = sep,
doi = {10.1093/ejendo/lvag167},
url = {https://hal.science/hal-05768445v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Long-acting growth hormone: an updated Growth Hormone Research Society consensus statement
AU - Katharina Schilbach
AU - Peter Clayton
AU - Nidhi Agrawal
AU - Mai Arlien-Søborg
AU - Philippe Backeljauw
AU - Beverly Biller
AU - Cesar Boguszewski
AU - Margaret Boguszewski
AU - Philippe Chanson
AU - Pierre Chatelain
AU - Stefano Cianfarani
AU - Maria Fleseriu
AU - Judith Gebauer
AU - Adda Grimberg
AU - Ken Ho
AU - Andrew Hoffman
AU - Gudmundur Johannsson
AU - Jens Jorgensen
AU - Anders Juul
AU - Wolfram Karges
AU - Jan Lebl
AU - Xiaoping Luo
AU - Mohamad Maghnie
AU - Aristides Maniatis
AU - Bradley Miller
AU - Sebastian Neggers
AU - Michel Polak
AU - Sally Radovick
AU - Lars Sävendahl
AU - Junia Schweizer
AU - Paulo Collett-Solberg
AU - Adam Stevens
AU - Christian Strasburger
AU - Christa van Bunderen
AU - Haim Werner
AU - Joachim Woelfle
AU - Kevin Yuen
AU - Martin Bidlingmaier
PY - 2026
DA - 2026/09/28
JO - European Journal of Endocrinology
DO - 10.1093/ejendo/lvag167
UR - https://hal.science/hal-05768445v1
AB - Long-acting growth hormone (LAGH) preparations have moved from development to routine clinical use over the past decade. Several products are now approved for paediatric growth hormone deficiency (GHD), selected non-GHD short-stature indications, and, in some regions, for adult GHD. The Growth Hormone Research Society convened an international workshop in October 2025 to reappraise the evidence base and refine clinical recommendations. Currently, data are available for up to 7 years of LAGH treatment in over 8000 individuals. This remains substantially shorter and smaller than for daily GH. Across preparations, short- to mid-term efficacy appears comparable to daily somatropin, provided dosing is individualized and monitored appropriately. Approvals and pivotal trials include both treatment initiation and switching from daily GH, depending on product and regional label. No new major safety signals have been identified in trials and real-world reports, although data on BMI trajectories require further evaluation. Injection-site reactions remain the most frequent adverse event and vary by formulation. Anti-drug antibodies have been observed, yet evidence suggests they have limited clinical impact. Effects on glucose metabolism resemble those of daily therapy, but metabolically, high-risk groups are under-represented in studies. Among cancer survivors, data on tumour recurrence and second neoplasms with LAGH are not yet available. Recommendations and practice points emphasized careful patient selection and counselling, product-specific dosing, and insulin-like growth factor-I (IGF-I) monitoring. Urgent knowledge gaps include transition care, long-term efficacy, adherence, and safety in cancer survivors. Well-resourced registries are essential for addressing these gaps and supporting safe, effective, and patient-centred use of LAGH.
SN - 0804-4643
SN - 1479-683X
ER -